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Abstract
Introduction: The aim of the study was to evaluate the efficacy of the endovascular ablation method of GSV/ 
/SSV superficial venous insufficiency using Flebogrif® catheter, the safety of the method, expressed in number 
and quality of observed complications in 24-month observation.
Material and methods: Initially, the observed group included 200 patients undergoing ablation of insufficient 
GSV/SSV. During 24 months of observation, this number decreased to 158, which seems to be a natural process. 
All patients signed the informed consent form approved by the Bioethics Committee of the Medical University 
of Lublin. Based on clinical evaluation, including ultrasound assessment, 200 patients, including 170 women 
and 30 men, were admitted to the study using the adopted criteria of inclusion/exclusion. In the studied group 
of patients, 172 great saphenous veins (GSV) and 28 short saphenous veins (SSV) were ablated. The treated 
inefficient veins were punctured at three levels depending on the length of the segment of insufficient GSV/SSV. 
Each patient was treated with a compression agent in the form of a second compression class elastic stockings 
(20–30 mm Hg). Control visits on the basis of the accepted protocol were established in 1, 3, 6, 12, 24, 36 
months after the procedure.
Results: During 24 months of observation, the evaluation of the Flebogrif® catheter method was based on the 
analysis of results obtained in four categories: effectiveness of the method, expressed as the ratio of the number 
of successfully closed veins ablated with the Flebogrif® catheter to the number of observed cases of recanaliza-
tion; clinical improvement of venous insufficiency symptoms, based on the VCSS, CEAP, VAPS scale; safety of 
the method, expressed in terms of quantity and quality of observed complications; technical characteristics 
of the method. The obtained results were analyzed statistically using tests for non-parametric variables. The 
effectiveness of the method based on the obtained results was 92%. A statistically significant decrease in the 
intensity of clinical symptoms in relation to the preoperative condition was observed. The number and quality of 
the observed complications allow considering the procedure of vein ablation with the use of Flebogrif® catheter 
as safe, possible to perform in ambulatory conditions.
Conclusions: Effectiveness of the method of 92% in 24-month observation; good cosmetic effect; a statis-
tically significant decrease in the intensity of clinical symptoms in 24-month observation; the low incidence of 
complications allows to consider the method safe; the method of surgery allows to perform the procedure in 
ambulatory conditions. 
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Introduction 
Venous insufficiency is a problem affecting a large part of 
the world population. It is estimated that about 1/3 of the 
population in developed countries suffers from venous 
insufficiency. In Europe, the proportion of the population 
affected by this disease is at a level of about 39% [1, 2]. 
Despite the many methods proposed over the 
centuries, the problem of GSV/SSV insufficiency seems 
to persist. The method developed in 1905 by Wil-
liam W. Babcock, based on stripping the trunk of 
the insufficient vein with minor modifications, still 
remains the basic procedure in classical surgery of 
lower limb varicose veins [3]. A number of mini-
mally invasive methods, such as EVLT, RFA, STIM 
introduced in the 1980s, constitute a compromise 
between patients’ expectations and therapeutic pos-
sibilities proposed by physicians dealing with the treat-
ment of superficial venous system insufficiency [4]. 
The method of mechano-chemical ablation with the 
use of Flebogrif® catheter, introduced by BALTON Sp. 
z o.o. seems to be an interesting proposal, extending 
the possibilities of effective solution of the problem of 
GSV/SSV insufficiency, perfectly matching the definition 
of the minimally invasive procedure [5, 6].
Material and methods 
The observed group of patients consisted of 200 
patients included in the study after signing the informed 
consent form approved by the Bioethics Committee of 
the Medical University of Lublin. Each patient met the 
exclusion criteria. The basis for qualification for the 
mechano-chemical ablation of superficial vein system 
insufficiency was Doppler ultrasound diagnosis of trunk 
insufficiency in one of the superficial veins system GSV/ 
/SSV. Demographic data and numerical distribution of 
patients treated with mechano-chemical ablation using 
Flebogrif® catheter are presented in Table 1. 
Before the procedure, the intensity of clinical 
symptoms was assessed according to Venous Clinical 
Severity Score (VCSS), CEAP (clinical, etiology, ana-
tomic, pathophysiologic) and visual analog pain scale 
in each patient. Based on ultrasound examination, the 
site of insufficient vein puncture was determined. For 
both GSV and SSV it was the lowest point of the insuf-
ficient vein segment. The numerical distribution of the 
puncture site is presented in Table 2. 
The procedure was carried out in a standard op-
erating room. The only form of analgesia used was 
anaesthesia of the sheath passage insertion site, which 
was the access point for the insertion of the Flebogrif® 
catheter. The ablation of insufficient veins using the 
Flebogrif® catheter was performed according to the 
IFU protocol enclosed by the manufacturer (Instruction 
for use). Mechanical endothelial damage was caused by 
the cutting elements of the catheter (five hooked bent 
“wires” towards the endothelial surface), while the 3% 
Polidocanol administered through the central channel 
of the catheter to the vessel lumen initiated inflamma-
tion, leading in the long term to fibrosis and permanent 
closure of the vein lumen. During the procedure, the 
great saphenous vein outlet to the femoral vein was 
closed by compression. The aim of this manoeuvre was 
to prevent inadvertent injection of a sclerosant into the 
deep vein system. After the procedure, each patient 
was provided with a compression agent in the form of a 
flexible stockings of pressure class II. The patients were 
discharged home within one hour after the procedure. 
Results 
VCSS, CEAP and Visual Analog Pain Scale (VAPS) were 
used to assess the clinical status of patients. Numer-
ical data obtained before the procedure, i.e., on the 
0-baseline day and at individual follow-up time points, 
were statistically analyzed using Anova Friedman test 
for non-parametric variables.
A statistically significant decrease in the total value 
was observed in individual time points in relation to 
day 0 — baseline, and the lowest value for the VCSS 
scale in 12 months was 4.40, with a standard deviation 
of 2.94, and P < 0.001. The difference in VCSS value 
between day, 12 and 24 months was not statistically 
significant (Table 3).
Graphical characteristics for the assessment of 
clinical condition using the VCSS scale are presented 
in Figure 1. 
Similar variability was observed in the case of the total 
values of the numerical data obtained for evaluation using 
the CEAP scale. The decrease in the numerical value 
for CEAP was statistically significant at all time points in 
relation to the 0-baseline day, with the largest decrease 
Table 1. Demographic data of patients included in the study
Gender n Age Total
Females 170 87 56 18 200
Males 30 75 46 23
Table 2. Numerical distribution of vein puncture site
          Gender
Puncture site
Aobove 
the knee
Knee  
level
Below  
the knee
n Total n Total n Total
Female 37
44
36
42
97
115
Male 7 6 18
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observed during the follow-up visit of 12 months: 2.99, 
with a standard deviation of 2.05 for P < 0.001 (Table 4).
Figure 2 presents a graphical characteristic for the 
discussed variability in the point value for CEAP scale 
in a 24-month observation. 
Numerical values for VAPS in 24-month observa-
tion showed a statistically significant decrease in indi-
vidual time points of observation, whereas between 
12 months and 24 months there were no statistically 
significant differences. The maximum decrease was 
observed during the 12-month visit: 0.60 with standard 
deviation of 0.86 for P < 0.001 (Table 5). 
The graphical illustration for the discussed variability 
of the VAPS scale is shown in Figure 3. 
Initial success was achieved in all patients. However, 
in the 24-month observation, cases of recanalization 
were observed, which were divided into two groups: 
partial and total recanalization. Table 6 shows the nu-
merical distribution of cases of recanalized veins taking 
into account sex, age, length of vein segment subjected 
Table 3. Variability in the point value for Venous Clinical Severity Score (VCSS) scale in 24-month observation
n min max M SD Me P
VCSS-B 200 3.00 21.00 10.72 3.96 9.00
< 0.001
VCSS-1 182 2.00 19.00 8.08 3.88 7.00
VCSS-3 179 1.00 16.00 5.79 3.52 5.00
VCSS-6 174 0.00 15.00 4.75 3.13 4.00
VCSS-12 168 0.00 15.00 4.40 2.94 4.00
VCSS-24 112 0.00 14.00 4,71 2.73 5.00
M: mean; SD: standard deviation; Me: median
Figure 1. Variability in the point value for Venous Clinical 
Severity Score (VCSS) scale in a 24-month observation 
Table 4. Variability in the point value for CEAP (clinical, etiology, anatomic, pathophysiologic) scale in a 24-month observation
n min max M SD Me P
CEAP-B 200 2.00 14.00 7.62 2.71 7.00
< 0.001
CEAP-1 182 1.00 12.00 5.48 2.54 5.00
CEAP-3 179 0.00 10.00 3.70 2.28 3.00
CEAP-6 174 0.00 10.00 3.20 2.13 3.00
CEAP-12 168 0.00 10.00 2.99 2.05 3.00
CEAP-24 113 0.00 10.00 3.39 2.04 4.00
M: mean; SD: standard deviation; Me: median
Figure 2. Graphical characteristics for the variability in the 
point value for CEAP (clinical, etiology, anatomic, pathophy-
siologic) scale in a 24-month observation
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to mechano-chemical ablation, amount of obliterating 
agent used and its concentration. 
Based on the classification of the European Con-
sensus on Sclerotherapy (Tagernsee 2006), the cases 
of recanalization are divided into two groups: the total 
and partial one [7]. Table 7 shows their numerical dis-
tribution by vein type and sex. 
No statistically significant correlation was found 
between the amount of obliterating agent, its concen-
tration, vein length, diameter and number of recanali-
zation at particular time points. 
In the observation between the visit of 12 months 
and 24 months, there were no further cases of com-
plications. 
Table 5. Variability in the point value for Visual Analog Pain Scale (VAPS) scale in a 24-month observation
n min max M SD Me P
VAPS-B 200 0.00 8.00 3.23 1.75 3.00
< 0.001
VAPS-1 182 0.00 7.00 1.88 1.43 1.00
VAPS-3 179 0.00 6.00 0.92 1.22 1.00
VAPS-6 174 0.00 6.00 0.72 1.06 0.00
VAPS-12 167 0.00 4.00 0.60 0.86 0.00
VAPS-24 112 0.00 4.00 0.64 0.89 0.00
M: mean; SD: standard deviation; Me: median
Figure 3. Graphical characteristics for the variability in 
the point value for Visual Analog Pain Scale (VAPS) scale 
in a 24-month observation
Table 6. Summary of recanalization cases including diameter, puncture site, amount of obliterating agent, vein length, age and sex
Age Leg Puncture site Vein Diameter v-foam 
(mL)
Lenght 
(cm)
Sex Recanalisation
R L – knee + GSV SSV SFJ VEIN F M F P
46 X X X 8.4 7.0 7.0 44 X X
48 X X X 7.2 5.9 6.0 43 X X
63 X X X 5.7 5.4 5.0 28 X X
47 X X X 9.0 7.2 6.0 31 X X
60 X X X 6.1 5.1 5.0 21 X X
56 X X X 8.4 8.0 8.0 41 X X
70 X X X 10.2 9.4 6.5 38 X X
74 X X X 7.7 5.8 5.0 29 X X
63 X X X 6.4 5.0 7.0 41 X X
63 X X X 7.6 7.4 5.0 24 X X
42 X X X 8.0 7.1 6.0 39 X X
61 X X X 8.1 7.3 7.0 41 X X
76 X X X 8.2 7.1 6.0 29 X X
39 X X X 9.6 8.3 5.0 23 X X
56 X X X 11.1 11.4 10 47 X X
R: right; L: left; GSV: great saphenous vein; SSV: short saphenous vein; SFJ: sapheno-phemoral junkction; VEIN: vein; F: female; M: male; F: full; P: partial
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Discussion 
The treatment of superficial venous insufficiencies 
with Flebogrif catheter is the youngest representative of 
mechano-chemical ablation procedures. Due to its low 
invasiveness, it can certainly be classified as a minimally 
invasive procedure. This position is supported by the 
opinion of patients undergoing the Flebogrif treatment, 
as well as physicians — Phlebologists performing the 
surgery [6, 8]. This is certainly not the final solution to 
the problem of venous insufficiency, but it should be 
stated that it broadens the possibilities of the treatment 
and is an interesting option especially in the context of 
the results obtained during the two-year observation. 
Thermal treatments developed in the early eighties 
of the last century like EVLT, RFA, have proven their 
effectiveness over the years, gaining in the opinion of 
experts the name of procedures recommended in the 
treatment of varicose veins of lower limbs caused by 
GSV/SSV insufficiency [3]. The later variant of thermal 
ablation with steam (STIM) also successfully applied 
to this group. Although the “STIM” method is not the 
most recommended treatment, it still finds a certain 
number of supporters [9–11]. An alternative to ther-
mal treatments is certainly the adhesive technique. 
The experience so far looks promising, but the scarce 
number of publications relating to its effectiveness and 
in particular the complications in long-term observa-
tion leaves some important questions unanswered. An 
interesting proposal is an obliteration by catheter (using 
a long and short catheter). Obtained indices of total 
effectiveness encourage its use. Especially the short 
catheter technique seems to be a good tool in case of 
curvilinear venous insufficiency, which is a problem and 
sometimes a disqualification criterion for other endo-
vascular procedures (EVLT, RFA, STIM) [12, 13]. It can 
be stated that the technique of catheter obliteration 
fits perfectly into the gap between classical intravenous 
procedures dedicated to trunk insufficiency with unfa-
vourable anatomy (winding course). Another positive 
feature of this technique is the possibility of its use in 
the obliteration of inefficient collateral and perforator 
veins. In this context, Flebogrif® is the only unique 
combination of both catheter ablation and mechanical 
endothelial surface destruction techniques typical of 
MOCA treatments (Clarivein) [14–17]. The versatil-
ity of the Flebogrif® catheter technique in both trunk 
and collateral insufficiency makes it an interesting and 
multi-purpose tool [6, 18]. This thesis is supported by 
the results of the method’s effectiveness in 24-month 
observation reaching 92%. By analyzing demographic 
data with particular regard to the increasing number of 
patients suffering from superficial venous insufficiency 
with regard to the efficacy, availability and acceptance 
by patients, we can conclude that we have a number 
of effective treatments, the combination of which al-
lows us to solve the problem of venous insufficiency 
almost completely. However, none of the currently used 
surgical methods solves the pathology of trunk insuf-
ficiency (GSV, SSV) on its own, which leaves the issue 
of lower limb varicose veins still open. On the other 
hand, we can consider whether, with such a variety of 
treatments with the possibilities defined only by the 
invention of the doctors performing the procedure, 
do we need one universal method, combining the 
advantages of the methods currently used, or does it 
really exist [19]? Reviewing literature reports on the 
effectiveness of individual types of procedures over 
a shorter or longer period of observation, we conclude 
that the percentages given allow us to formulate a list of 
the most recommended ones, among which Flebogrif® 
is in the upper range. Assessing the availability of in-
dividual treatments, which is primarily determined by 
economic relations, i.e., the patient’s purchasing power 
in correlation with the proposed price indices, we can 
conclude that Flebogrif® occupies a leading position. In 
conclusion, we would like to emphasize once again that 
the Flebogrif® catheter technique proposed by us is not 
in competition with other methods, if only because of 
fundamental methodological differences. 
Acceptance of patients and growing interest in the 
method motivates us to continue using it. 
Conclusions
1. Effectiveness of the method on a level of 92% in 
24-month observation. 
2. Good cosmetic effect. 
3. Statistically significant decrease in the intensity of 
clinical symptoms in 24-month observation. 
4. Low incidence of complications allows to consider 
the method safe. 
5. The method of treatment allows to perform the 
procedure in ambulatory conditions.
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Table 7. Numerical distribution by vein, type and sex  
of racanalisation cases
Females Males
GSV SSV GSV SSV
P F P F P F P F
1 9 1 2 2 0 0 0
P: partial; F: full; GSV: great saphenous vein; SSV: short saphenous vein
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